Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
Company profile
Ticker
NVO, NONOF
Exchange
Website
CEO
Lars Fruergaard Joergensen
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
NVO stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
18 Mar 24
6-K
Current report (foreign)
11 Mar 24
6-K
Current report (foreign)
8 Mar 24
6-K
Current report (foreign)
5 Mar 24
6-K
Current report (foreign)
4 Mar 24
6-K
Current report (foreign)
26 Feb 24
6-K
Current report (foreign)
22 Feb 24
6-K
Current report (foreign)
22 Feb 24
6-K
Current report (foreign)
14 Feb 24
6-K
Current report (foreign)
13 Feb 24
Latest ownership filings
SC 13G/A
BlackRock Inc.
6 Feb 24
11-K
Annual report of employee stock purchases
27 Jun 23
11-K
Annual report of employee stock purchases
27 Jun 23
SC 13G/A
BlackRock Inc.
23 Feb 23
11-K
Annual report of employee stock purchases
28 Jun 22
11-K
Annual report of employee stock purchases
28 Jun 22
SC 13G/A
BlackRock Inc.
1 Feb 22
11-K
Annual report of employee stock purchases
23 Jun 21
11-K
Annual report of employee stock purchases
23 Jun 21
SC 13G/A
BlackRock Inc.
29 Jan 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
7.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1239 |
Opened positions | 228 |
Closed positions | 268 |
Increased positions | 476 |
Reduced positions | 367 |
13F shares | Current |
---|---|
Total value | 21.64 tn |
Total shares | 246.27 mm |
Total puts | 504.88 k |
Total calls | 1.72 mm |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Jennison Associates | 22.53 mm | $2.33 tn |
Fisher Asset Management | 14.13 mm | $1.46 tn |
Renaissance Technologies | 13.85 mm | $1.43 bn |
FMR | 12.66 mm | $1.31 tn |
Fayez Sarofim & Co | 11.81 mm | $1.43 tn |
MS Morgan Stanley | 10.61 mm | $1.10 tn |
Loomis Sayles & Co L P | 9.00 mm | $931.39 mm |
Folketrygdfondet | 8.63 mm | $892.90 bn |
Polen Capital Management | 7.96 mm | $823.30 bn |
T. Rowe Price | 7.77 mm | $803.41 mm |
News
Inconsistent Insurance Coverage For Weight Loss Drugs - Novo Nordisk's GLP-1s Face Hurdles Despite Health Benefits
18 Mar 24
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
18 Mar 24
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
18 Mar 24
Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
15 Mar 24
Smart Money Is Betting Big In NVO Options
14 Mar 24
Press releases
Thinking about trading options or stock in Apple, Pfizer, Taiwan Semiconductor, Microsoft, or Novo Nordisk?
12 Mar 24
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
8 Mar 24
Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease
26 Feb 24
Thinking about trading options or stock in Tesla, Microsoft, Novo Nordisk, Intel, or Solaredge Technologies?
7 Feb 24
Thinking about buying stock in NKGen Biotech, Novo Nordisk, SoundHound AI, Safety Shot, or Energy Fuels?
1 Feb 24